Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine +/- IL-2 in Metastatic Melanoma
NCT00019214Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1997
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of MART-1-pulsed dendritic cells + gp100-pulsed dendritic cells in melanoma (3 arms), sponsored by National Cancer Institute. Primary endpoints: Toxicity and Maximum Tolerated Dose. Started Apr 1997; status: completed.
02
Drugs
MART-1-pulsed dendritic cells + gp100-pulsed dendritic cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019214.